Global capacity US Pharma Lab operates with over 500,000 sq. ft of NSF cGMP-certified and US FDA-audited manufacturing space across the United States and China, indicating scalable production capacity and potential for volume manufacturing partnerships.

Acquisition leverage The 2023 acquisition by Biofarma Group creates a broader global network (eight manufacturing sites across Europe, America, and Asia) and a wider CDMO footprint, enabling cross-sell opportunities to Biofarma’s existing customers and enhanced co-manufacturing options.

Nutraceutical leadership Positioned as a leader in quality, consistency, and innovation within the nutraceutical space, US Pharma Lab can target premium ingredient suppliers, contract development, and packaged product opportunities to brands seeking reliable, high-quality manufacturing partners.

Strategic partnerships Historical collaboration with OptiBiotix and a track record of manufacturing and supply agreements suggest openness to long-term CMO relationships with R&D-driven customers, including obesity, cholesterol, diabetes, and skin-care related programs.

Growth-ready profile Revenue in the $100M–$250M range combined with the Biofarma Group backing and a diverse tech stack positions US Pharma Lab as a scalable partner for mid-market to large brands looking to expand or co-manufacture nutraceutical, dietary supplement, and related product lines.